Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Long-Term Deferred Tax (2022 - 2025)

Sonoma Pharmaceuticals has reported Long-Term Deferred Tax over the past 4 years, most recently at $458000.0 for Q4 2025.

  • For Q4 2025, Long-Term Deferred Tax fell 39.74% year-over-year to $458000.0; the TTM value through Dec 2025 reached $458000.0, down 39.74%, while the annual FY2025 figure was $589000.0, 48.56% down from the prior year.
  • Long-Term Deferred Tax for Q4 2025 was $458000.0 at Sonoma Pharmaceuticals, down from $508000.0 in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $1.1 million in Q1 2024 and troughed at $458000.0 in Q4 2025.
  • A 4-year average of $817000.0 and a median of $849500.0 in 2022 define the central range for Long-Term Deferred Tax.
  • Biggest five-year swings in Long-Term Deferred Tax: increased 20.65% in 2024 and later plummeted 48.56% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $1.1 million in 2022, then fell by 15.34% to $922000.0 in 2023, then decreased by 17.57% to $760000.0 in 2024, then crashed by 39.74% to $458000.0 in 2025.
  • Business Quant data shows Long-Term Deferred Tax for SNOA at $458000.0 in Q4 2025, $508000.0 in Q3 2025, and $546000.0 in Q2 2025.